It has been suggested that a loss of p53 function in CLL cells with 17p-deletion maybe a major factor contributing to the drug resistance and poor clinical outcome of this subgroup of patients [5–6]. The gene discussed is TP53; the disease is B-cell chronic lymphocytic leukemia.